Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp RVXCF


Primary Symbol: T.RVX

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024

Newsfile September 3, 2024

Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension

Newsfile July 31, 2024

Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges

Newsfile July 16, 2024

Resverlogix Announces Updated Annual and Special Meeting of Shareholders

Newsfile May 28, 2024

Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges

Newsfile May 13, 2024

Resverlogix Announces Change to Its Board of Directors

Newsfile February 21, 2024

Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

Newsfile January 11, 2024

Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Newsfile October 4, 2023

Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes

Newsfile August 29, 2023

Resverlogix Announces Warrant Repricing and One-Year Extension

Newsfile June 29, 2023

Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders

Newsfile June 20, 2023

Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients

Newsfile June 12, 2023

Resverlogix Announces One-Year Extension of Debenture

Newsfile March 20, 2023

Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19

Newsfile March 2, 2023

Resverlogix (TSX:RVX) focuses drug development on COVID-19

Caroline Egan  September 28, 2022

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

GlobeNewswire September 28, 2022

Resverlogix (TSX:RVX) highlights apabetalone's benefit in non-alcoholic fatty liver disease

Azuka Onwuka August 22, 2022

Resverlogix Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease

GlobeNewswire August 22, 2022

Resverlogix Announces Appointment of New Chief Scientific Officer

GlobeNewswire August 15, 2022

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

GlobeNewswire June 21, 2022